A Bayesian analysis of doubly censored data using a hierarchical Cox model

Statistics in Medicine

Volumn 27, Issue 4, 2008, Pages 529-542

  Zhang, Wei ^a,b   Chaloner, Kathryn ^a   Cowles, Mary Kathryn ^a   Zhang, Ying ^a   Stapleton, Jack T ^c  

^a UNIVERSITY OF IOWA   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

GBV C; Human immunodeficiency virus; Interval censoring; MCMC; Multicenter AIDS cohort study; Partial likelihood

Indexed keywords

ARTICLE; BAYES THEOREM; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE PREDISPOSITION; HAZARD RATIO; HEPATITIS G; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MULTICENTER STUDY; ONSET AGE; OVERALL SURVIVAL; POPULATION DISTRIBUTION; POPULATION RISK; PREVALENCE; PROPORTIONAL HAZARDS MODEL; QUALITATIVE ANALYSIS; SEROCONVERSION; STATISTICAL MODEL; SUPERINFECTION; SURVIVAL; SURVIVAL TIME;

BAYES THEOREM; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; GB VIRUS C; HIV INFECTIONS; HUMANS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 39449093656     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3002     Document Type: Article

References (50)

1. Alter HJ. The cloning and clinical implications of HGV and HGBV-C. The New England Journal of Medicine 1996; 334: 1536-1537.
2. Rambusch EG, Wedemeyer H, Tillmann HL, Heringlake S, Manns MP. Significance of coinfection with hepatitis G virus for chronic hepatitis C - a review of the literature. Zeitschrift fur Gastroenterologie 1998; 36:41-53.
3. Tillmann HL, Heringlake S, Trautwein C, Meissner D, Nashan B, Schlitt HJ, Kratochvil J, Hunt J, Qiu X, Lou SC, Pichlmayr R, Manns MP. Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatology 1998; 28:379-384.
4. Stapleton JT. GB virus type C/hepatitis G virus. Seminars in Liver Disease 2003; 23:137-148.
5. Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, Petit JC, Lerable J, Thauvin M, Mariotti M. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. Journal of Infectious Diseases 1999; 179:783-789.
6. Xiang J, Wünschmann S, Diekema DJ, Klinzman D, Patrick KD, George SL, Stapleton JT. Effect of coinfection with GB virus C on survival among patients with HIV infection. The New England Journal of Medicine 2001; 345:707-714.
7. Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, Goergen B, Detmer J, McMorrow M, Stoll M, Schmidt RE, Manns MP. Infection with GB virus C and reduced mortality among HIV-infected patients. The New England Journal of Medicine 2001; 345:715-724.
8. Williams CF, Klinzman D, Yamashita TE, Xiang J, Polgreen PM, Rinaldo C, Liu C, Phair J, Margolick JB, Zdunek D, Hess G, Stapleton JT. Persistent GB virus C infection and survival in HIV-infected men. The New England Journal of Medicine 2004; 350:981-990.
9. Björkman P, Flamhotc L, Nauclér A, Molnegren V, Wallmark E, Widell A. GB virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality. AIDS 2004; 18:877-886.
10. Birk M, Lindback S, Lidman C. No influence of GB virus C replication on the prognosis in a cohort of HIV-1-infected patients. AIDS 2002; 16:2482-2485.
11. Zhang W, Chaloner K, Tillmann HL, Williams CF, Stapleton JT. Effect of early and late GBV-C viremia on survival of HIV infected individuals: a meta-analysis. HIV Medicine 2006; 7:173-180.
12. Stapleton JT, Chaloner K, Williams CF. GB virus C infection and survival in the Amsterdam cohort study. Journal of Infectious Diseases 2005; 191:2157-2158.
13. Van der Bij AK, Kloosterboer N, Prins M, Boeser-Nunnink B, Geskus RB, Lange JM, Coutinho RA, Schuitemaker H. Reply to George and Stapleton et al. Journal of Infectious Diseases 2005; 191:2158-2160.
14. Cox DR. Regression models and life-tables (with discussion). Journal of the Royal Statistical Society, Series B 1972; 34:187-200.
15. Clayton DG. A model for association in bivariate life tables and its applications in epidemiological studies of familial tendency in chronic disease indigence. Biometrika 1978; 65:141-151.
16. Clayton DG, Cuzick J. Multivariate generalizations of the proportional hazards model. Journal of the Royal Statistical Society, Series A 1985; 148:82-117.
17. Gustafson P. A Bayesian analysis of bivariate survival data from a multicenter cancer clinical trial. Statistics in Medicine 1995; 14:2523-2535.
18. Stangl D. Prediction and decision making using Bayesian hierarchical models. Statistics in Medicine 1995; 14:2173-2190.
19. Stangl D, Greenhouse J. Assessing placebo response using Bayesian hierarchical survival models. Lifetime Data Analysis 1998; 4:5-28.
20. Sargent DJ. A general framework for random effects survival analysis in the Cox proportional hazards setting. Biometrics 1998; 54:1486-1497.
21. Gustafson P. Large hierarchical Bayesian analysis of multivariate survival data. Biometrics 1997; 53:230-242.
22. Cox DR. Partial likelihood. Biometrika 1975; 62:269-275.
23. Kalbfleisch JD. Nonparametric Bayesian analysis of survival time data. Journal of the Royal Statistical Society, Series B 1978; 40:214-221.
24. Sinha D, Ibrahim JG, Chen M. A Bayesian justification of Cox's partial likelihood. Biometrics 2003; 90:629-641.
25. Ibrahim JG, Chen M-H, Sinha D. Bayesian Survival Analysis. Springer: New York, 2001.
26. Chen M-H, Ibrahim JG, Shao Q-M. Posterior propriety and computation for the Cox regression model with applications to missing covariates. Biometrika 2006; 93:791-807.
27. Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH, Teller E. Equations of state calculations by fast computing machines. Journal of Chemical Physics 1953; 21:1087-1092.
28. Hastings WK. Monte Carlo sampling methods using Markov chains and their applications. Biometrika 1970; 57:97-109.
29. Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice. Chapman & Hall: London, 1996.
30. Liu KJ, Darrow WW, Rutherford GW. A model-based estimate of the mean incubation period for AIDS in homosexual men. Science 1988; 240:1333-1335.
31. Mariotto AB, Mariotti S, Pezzotti P, Rezza G, Verdecchia A. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. American Journal of Epidemiology 1992; 135:428-437.
32. Law CG, Brookmeyer R. Effects of mid-point imputation on the analysis of doubly censored data. Statistics in Medicine 1992; 11:1569-1578.
33. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. Journal of the Royal Statistical Society, Series B 1976; 38:290-295.
34. Jaffe HW, Darrow WW, Echenberg DF, O'Malley PM, Getchell JP, Kalyanaraman VS, Byers RH, Drennan DP, Braff EH, Curran JW et al. The acquired immunodeficiency syndrome in a cohort of homosexual men: a six year follow-up study. Annals of Internal Medicine 1985; 103:210-214.o
35. Souza IE, Allen JB, Xiang J, Klinzman D, Diaz R, Zhang S, Chaloner K, Zdunek D, Hess G, Williams CF, Benning L, Stapleton JT. Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia. Journal of Clinical Microbiology 2006; 44:3105-3113.
36. Toyoda H, Fukuda Y, Hayakawa T, Takamatsu, Saito H. Effect of GB virus C/ hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1998; 17:209-213.
37. Zhang W, Chaloner K, Cowles MK, Zhang Y, Stapleton JT. A Bayesian analysis of doubly censored data using a hierarchical Cox model. Technical Report, Department of Biostatistics at University of Iowa, 2007 (Available from: http://www.public-health.uiowa.edu/biostat/ research/reports.html).
38. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria. ISBN: 3-900051-07-0 (Available from: http://www.r-project.org, 2005).
39. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS User Manual, 2003 (Available from: http://www.mrc-bsu.cam.ac.uk/bugs).
40. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998; 7:434-455.
41. Tanner MA, Wong WH. The calculation of posterior distributions by data augmentation. Journal of the American Statistical Association 1987; 82:528-540.
42. Härkänen T, Virtanen JI, Arjas E. Caries on permanent teeth: a non-parametric Bayesian analysis. Scandinavian Journal of Statistics 2000; 27:577-588.
43. Komárek A, Lesaffre E, Härkänen T, Declerck D, Virtanen JI. A Bayesian analysis of multivariate doubly-interval-censored dental data. Biostatistics 2005; 6:145-155.
44. Bisson GP, Strom BL, Gross R, Weissman D, Klinzman D, Hwang WT, Kostman JR, Metzger D, Stapleton JT, Frank I. Effect of GB virus C viremia on HIV acquisition and HIV set-point. AIDS 2005; 19:1910-1912.
45. Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, Stapleton JT. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. The Lancet 2004; 363:2040-2046.
46. Jung S, Knauer O, Donhauser N, Eichenmüller M, Helm M, Fleckenstein B, Reil H. Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors. AIDS 2005; 19:1267-1272.
47. Nattermann J, Nischalke HD, Kupfer B, Rockstroh J, Hess L, Sauerbruch T, Spengler U. Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS 2003; 17:1457-1462.
48. Xiang J, Sathar MA, McLinden JH, Klinzman D, Chang Q, Stapleton JT. South African GB virus C isolates: interactions between genotypes 1 and 5 isolates and HIV. Journal of Infectious Diseases 2005; 192:2147-2151.
49. George SL, Varmaz D, Stapleton JT. GB virus C replicates in primary T and B lymphocytes. Journal of Infectious Diseases 2006; 193:451-454.
50. Stiehm ER. Disease versus disease: how one disease may ameliorate another. Pediatrics 2006; 117:184-191.